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Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and can vary from benign
steatosis to end-stage liver disease. The pathogenesis of non-alcoholic steatohepatitis (NASH) is currently thought to involve
a multiple-hit process with the ﬁrst hit being the accumulation of liver fat which is followed by the development of
necroinﬂammation and ﬁbrosis. There is mounting evidence that cytokines secreted from adipose tissue, namely, adipokines,
are implicated in the pathogenesis and progression of NAFLD. In the current review, we explore the role of these adipokines,
particularlyleptin,adiponectin,resistin,tumornecrosisfactor-a,andinterleukin-6inNASH,aselucidatedinexperimentalmodels
and clinical practice. We also comment on their potential use as noninvasive markers for diﬀerentiating simple fatty liver from
NASH as well as on their potential future therapeutic role in patients with NASH.
Copyright © 2009 Emmanuel A. Tsochatzis et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Nonalcoholic fatty liver disease (NAFLD) is the hepatic
manifestation of the metabolic syndrome and is closely
associated with visceral obesity and insulin resistance [1–3].
The prevalence of NAFLD is 10–25% in the western world
[4–6]; only in USA, an estimated number of 80 million
adults are aﬀected [7]. The term NAFLD encompasses a
wide spectrum of liver histology, from simple steatosis to
nonalcoholic steatohepatitis (NASH), which can progress
to cirrhosis and its complications [7]. The pathogenesis
of NASH is currently thought to involve a multiple step
process, in which the ﬁrst step is the accumulation of liver fat
which is followed by the development of necroinﬂammation
and ﬁbrosis [8]. Distinguishing NAFLD from NASH is
essential in the clinical setting, as NAFLD seems to have a
benign course in the absence of co-existing liver disease, in
sharp contrast to NASH, which is associated with increased
morbidity and mortality and a reduced life expectancy
[9, 10]. Although noninvasive clinical markers have been
proposed, liver biopsy still remains the gold standard for the
above distinction [11].
Cytokines play a pivotal role in pathogenesis and severity
of NAFLD. In the last decade, adipose tissue has emerged as
an endocrine organ with a key role in energy homeostasis,
since its metabolic products, adipokines, exert local, periph-
eral, and central eﬀects [12]. Obesity is currently regarded as
a systemic, low-grade inﬂammation, in which adipose tissue
and its hormones have a central role [13]. Hypertrophied
adipocytes release chemokines, which recruit macrophages
and a vicious cycle commences, as macrophages release
inﬂammatory cytokines, which stimulate inﬂammatory and
suppressanti-inﬂammatoryadipokines[14].Inthesettingof
liver injury, most adipokines are also produced and secreted
by hepatocytes. In the current review, we explore the role
of cytokines in the clinical setting of NAFLD, in terms of
pathogenesis, their use as markers of disease progression
and their perspective as therapeutic targets. We particularly
focus on adipokines, namely, leptin, adiponectin, and
resistin, tumour necrosis factor-a (TNFa) and interleukin-
6 (IL-6) and we brieﬂy discuss the potential role of
recently discovered visfatin and retinol-binding protein
4 (RBP4).2 Mediators of Inﬂammation
2. CytokinesandNAFLD—Experimental
Models
2.1. NAFLD and NASH: Pathophysiology. The primary insult
in NASH is accumulation of triglycerides in the liver, as a
resultofinsulin resistance[7].Themaineﬀectofinsulinisto
increase glucose uptake by cells through upregulation of the
glucose transporters expression on the cells surface. Insulin
also induces lipogenesis and inhibits lipolysis in the adipose
tissue [15], while it increases the synthesis of fatty acids in
the liver. Insulin resistance and the metabolic syndrome lead
to defective insulin-mediated inhibition of lipolysis, mostly
in visceral fat, while hyperinsulinemia results in increased
hepatic synthesis of free fatty acids and decreased synthesis
of apolipoprotein B-100. Thus, insulin resistance results in
both increased adipose tissue lipolysis and increased hepatic
lipogenesis leading to lipid accumulation in the hepatocytes,
mainly in the form of triglycerides [16].
According to the “two-hit” hypothesis, the development
of NASH requires the presence of additional pathophysio-
logical abnormalities. The second hit is currently believed to
be increased oxidative stress within the hepatocytes, which
is characterized by excessive production of reactive oxygen
species (ROS) [17]. Mitochondria and the cytochrome P-450
systemareconsideredtobethemajorROSgenerationsitesin
the liver [17, 18]. ROS promote progression from steatosis to
steatohepatitis and ﬁbrosis by three main mechanisms: lipid
peroxidation, cytokine induction, and Fas ligand induction
[19–21]. It must be noted that as the term two-hit might
be too simplistic to elaborate the complex pathogenic events
occurring in NASH patients, multiple-step models taking
into account that lipid injury to hepatic veins have been
formed [22]. In this complex setting, the role of various
adipokines has been clearly elucidated.
2.2. Leptin. Leptin is a 167-amino acid protein discovered
by positional cloning of the ob gene in 1994 [23]. Although
it is considered as an anorexigenic hormone, its levels are
elevated in obesity as a result of resistance to its actions
[24]. In animal models, it prevents lipid accumulation in
nonadipose tissues [25]. In particular in the liver, this eﬀect
is achieved by lowering the expression of sterol regulating
binding protein 1 (SREBP-1) [26]. Leptin is thought to
participate in both hits of NASH development. Initially, it
contributes to the development of insulin resistance and
subsequently steatosis. Furthermore, in the context of liver
insult,leptinhasaproinﬂammatoryroleandisconsideredto
be an essential mediator of liver ﬁbrosis [12]. In rats treated
with carbon tetrachloride (CCl4), leptin injections have been
shown to result in increased expression of procollagen-I,
transforming growth factor β1( T G F β1) and smooth muscle
actin, a marker of activated hepatic stellate cells (HSCs), and
eventually to increased liver ﬁbrosis [27]. In the latter study
[27], there was also a dramatic increase in serum TNFa levels
after leptin injections, suggesting that leptin may amplify
inﬂammation and independently aﬀect the development of
ﬁbrosis [28]. Sinusoidal endothelial cells and Kupﬀer cells
were identiﬁed as the main targets of the proﬁbrogenic
action of leptin [27]. On the other hand, leptin-resistant [29]
or leptin-deﬁcient mice [30] exhibit signiﬁcantly reduced
ﬁbrogenic responses. This ﬁbrogenic eﬀect is accomplished
through HSCs, in which leptin is a potent mitogen and
apoptosis inhibitor. Activated HSCs acquire the ability to
secrete leptin and further promote liver ﬁbrosis [12].
2.3. Adiponectin. Adiponectin is exclusively secreted by
adipocytes and is considered as an anti-inﬂammatory
adipokine [31]. It reduces body fat, improves hepatic and
peripheral insulin sensitivity, and is inversely associated with
body mass index and insulin resistance [32]. In the liver,
it prevents lipid accumulation by increasing β-oxidation
of free fatty acids and/or by decreasing de novo free fatty
acids within hepatocytes [33, 34]. Part of this action is
accomplished through the downregulation of SREBP-1, a
key regulator of fatty acid synthesis [35]. As a result of
the above, adiponectin knockout mice develop more severe
hepatic steatosis than wild-type mice when fed with a diet
aiming to induce NASH [36]. Furthermore, adiponectin
has a protective role in liver inﬂammation and ﬁbrosis;
in their classic experiment, Kamada et al. showed that
adiponectin treatment attenuated liver ﬁbrosis in mouse
models treated with CCl4 and that HSCs express both
adiponectin receptors (AdipoR1 and AdipoR2). Using a
mouse model of endotoxin induced acute liver injury in KK-
Ay obese mice, Masaki et al. found that adiponectin prevents
hepatic injury by inhibiting the synthesis and/or release of
TNFa [37], while Xu et al. also observed a protective eﬀect
of adiponectin in fatty liver disease in mice [38]. In another
mouse model, the adiponectin resistance and sensitivity
mediated by adipoR2 regulated NASH progression and
this was accomplished by changing PPARa activity and
ROS accumulation. The authors thus concluded that the
liver adipoR2 signalling pathway could be a promising
target in treating NASH [39]. Finally, adiponectin induction
was associated with the protective action of saturated fat
against the development of alcoholic fatty liver disease in
mice [34].
2.4. Tumour Necrosis Factor-a. TNFa has also a central role
in the development of fatty liver and subsequently NASH.
Elevated circulating TNFa levels are associated with obesity
and insulin resistance both in animal models and humans
[40, 41]. The lipogenic action of TNFa is in part accom-
plished by the upregulation of SREBP-1 [34]. Furthermore,
the 238 TNFa gene polymorphism was found signiﬁcantly
more frequently in patients with fatty liver than healthy
controls [42] and the 1031C and 863A polymorphisms
in NASH than fatty liver [43]. Moreover, elevated TNFa
pr oductionhasbeenobserv edincultur esofperipheralblood
cells collected from obese patients with NASH [44]. Mice
genetically deﬁcient in TNF receptor I have proved resistant
to NASH induced by two diﬀerent diets [45, 46], while
treatment of leptin-deﬁcient mice with TNFa antibodies
improvedhepaticinsulinresistanceandfattyliver[47].Itwas
further suggested that TNFa proﬁbrotic action is mediated
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2.5. Resistin. Resistin is a recently discovered adipokine,
secreted by adipose tissue and macrophages [48]. A number
of rodent studies suggest that the major target of resistin
action is the liver, causing hepatic insulin resistance, with
additional eﬀects on skeletal muscles and adipose tissue
[49–52]. In skeletal muscle, it seems to reduce the uptake
and metabolism of free fatty acids, thus contributing to
insulin resistance [53]. Moreover, there is evidence that
resistin treatment markedly induces the gene expression
of suppressor of cytokine signalling 3 (SOCS3), a known
inhibitorofinsulinsignalling[54].Mostimportantly,thereis
evidenceofaproinﬂammatoryresistinaction,asitstimulates
TNFa and IL-12 in macrophages by a nuclear factor (NF)-
kappaB-dependent pathway [55] and regulates the secretion
of IL-6 and IL-1β [56]. Finally, evidence from one study
suggests that resistin has a proinﬂammatory action in HSCs,
thus participating in liver ﬁbrogenesis [57].
2.6. Interleukin-6. The issue seems to be more complex
with IL-6, a cytokine secreted by adipocytes, immune, and
endothelial cells. Initial reports supported a hepatoprotective
action of IL-6 in steatotic livers, by suppressing oxidative
stress and preventing mitochondrial dysfunction [58, 59].
M o r e o v e r ,I L - 6h a sah e p a t o p r o t e c t i v ee ﬀect in ischaemic
preconditioning models [60] and is important for survival
after partial hepatectomy in mice [61]. However, this seems
to be a paradoxical eﬀect of short- and long-term IL-6
exposure, as the latter may sensitize the liver to injury and
apoptotic cell death [62]. It remains to be elucidated whether
elevated IL-6 levels in chronic liver injury contribute to
inﬂammation or represent an anti-inﬂammatory response.
2.7. Other Cytokines. RBP4 is predominantly secreted by
visceral adipose tissue and is elevated in the insulin-resistant
state [63]. A pathogenetic link of elevated adipose and serum
levels of RBP4 with insulin resistance and diabetes has been
found in both animal and human studies [63–65]. Moreover,
RBP4 levels were associated with the inﬂammatory response
in obese individuals [66, 67].
Visfatin is a recently discovered adipokine that exerts
insulin-mimicking eﬀects, by activating the insulin receptor
in a manner distinct from that of insulin [68]. There is
evidence that supports a possible coregulation with IL-6, as
visfatin induces the production of IL-6 in human CD4 [59],
whereas IL-6 negatively regulates visfatin gene expression in
3T3-LI adipocytes [60]. There are currently no studies to
support a pro- or anti-inﬂammatory visfatin action.
3. CytokinesandNASH—Human Studies
The above observations in experimental models of steatosis
and liver injury, elucidating a potential association of various
cytokinesinthedevelopmentofNASH,haveresultedintheir
evaluation in patients with NASH.
The ﬁrst adipokine to be addressed was leptin, with
contradictory results. Leptin levels were initially found to be
signiﬁcantly higher in 47 NASH patients than 47 controls
and correlated with the severity of hepatic steatosis but not
of necroinﬂammation or ﬁbrosis [69] .T h r e em o r es t u d i e s ,
comprising of 88, 26, and 25 patients, respectively, [70–
72], failed to show any signiﬁcant diﬀerence in leptin levels
between NASH and controls or any independent association
with liver ﬁbrosis. In a recent study, we showed that leptin
levels are signiﬁcantly higher in NASH patients than patients
with chronic viral hepatitis and correlate with more severe
ﬁbrosis in univariate analysis [73]. Other studies have also
reported conﬂicting results [74]. Thus, it is doubtful whether
leptin is upregulated in patients with NASH and larger
studies with homogenous population and carefully matched
healthycontrolsareneeded.Forthetimebeing,leptincannot
be used as a noninvasive marker for the diagnosis of NASH.
Results have been more promising with adiponectin, as
its levels are lower in patients with NAFLD/NASH than
controls [75]. Furthermore, important steps have been taken
towards its use as a noninvasive marker for the diﬀer-
entiation between NAFLD and NASH. Hui et al. showed
that adiponectin was signiﬁcantly reduced in subjects with
NASH compared to age, BMI, and sex matched healthy
controls or compared to patients with simple steatosis [76].
The authors found that the combined use of adiponectin
and homeostasis model assessment for insulin resistance
(HOMA-IR) for diﬀerentiating NASH from fatty liver had
an area under the curve value of 0.79. Attempting to set
a discriminating adiponectin level, they found that 77%
of patients with NASH had adiponectin <10μg/mL and
HOMA-IR >3, compared to 33% of patients with simple
steatosis. In another study comprising of 66 patients with
early NASH stages (Brunt 1-2) and 19 with simple steatosis,
the combined evaluation of serum adiponectin, HOMA-
IR, and serum collagen type IV had 94% sensitivity and
74% speciﬁcity for the prediction of early NASH [77].
When adiponectin was used alone, the area under the
receiver operating characteristic (ROC) curve was 0.765 for
the above prediction. Finally, in 101 obese patients with
NASH, a biomarker panel comprised of cleaved cytokeratin
18 (CK-18), adiponectin, and resistin had 95% sensitivity
and 70% speciﬁcity for diagnosis [78]. All three mentioned
studies have yielded promising results towards a noninvasive
method of diagnosing NASH. The measurement of high
molecular weight adiponectin levels, which are thought to
better correlate with steatosis than the total adiponectin
levels [79] and the validation of these markers in larger
cohorts would be crucial steps towards the widespread use
of these biomarker panels.
Apart from adiponectin serum levels, the hepatic and
adipose expression of its receptors have been measured with
conﬂicting results. In the largest study, adiponectin receptors
were underexpressed in visceral fat but overexpressed in liver
andpositivelyassociatedwithliverdamage[80].Theauthors
concluded that the liver overexpression possibly constituted
a compensatory response to hypoadiponectinemia. Two
smaller studies, however, yielded contradictory results, as
they found that hepatic expressions of adiponectin mRNA
and adipoR2 receptor were signiﬁcantly lower in NASH
patients compared with patients with fatty liver [81, 82].
In a recent study, single nucleotide adiponectin polymor-
phisms (SNPs) were studied in 70 nonobese, nondiabetic,4 Mediators of Inﬂammation
Table 1: The role of diﬀerent adipokines in NAFLD.
Cytokine Experimental models Clinical studies
Leptin Proinﬂammatory Not elevated in NAFLD/NASH
HSCs activation No association with histology
Adiponectin Anti-inﬂammatory Lower in NAFLD than controls
Hepatoprotective Inversely correlates with ﬁbrosis
Resistin Proinﬂammatory Elevated in NASH
Possible association with ﬁbrosis
TNF-a Proinﬂammatory Elevated in NAFLD/NASH
Lipogenic Correlates with ﬁbrosis
IL-6 Uncertain Insuﬃcient evidence
Visfatin Uncertain Insuﬃcient evidence
RBP-4 Proinﬂammatory Insuﬃcient evidence
TNF-a: tumour necrosis factor-a; IL-6: interleukin-6; RBP-4: retinol-binding protein-4; HSCs: hepatic stellate cells;NAFLD: nonalcoholic fatty liver disease;
NASH: nonalcoholic steatohepatitis.
normolipidemic NAFLD patients, and 70 healthy controls.
Interestingly, it was shown that two at-risk adiponectin SNPs
(45TT and 276GT) were signiﬁcantly more prevalent in
NAFLD than in the general population, and that they were
associated with severity of liver disease independently of
adiponectin serum levels [83]. As genetic testing is due to
become readily available, future use of SNPs as noninvasive
disease markers may be feasible.
Results are contradictory in the case of TNFa and might
reﬂect diﬀerent study populations or the lack of adjustment
for several factors that may inﬂuence its serum levels. Hui
et al. showed that although TNFa levels signiﬁcantly diﬀered
between NAFLD and controls, no such diﬀerence existed
between NASH and NAFLD [76]. In a small study of 23
patients with NASH, 21 with NAFLD and 18 controls,
serum TNFa and soluble TNF receptor 1 were signiﬁcantly
increased in NASH compared to both NAFLD and controls
[84]. Finally, no signiﬁcant diﬀerence of serum TNFa levels
was found between a population of nonobese nondiabetic
NASH patients and matched controls [72].
Resistin is inadequately studied in NASH, and clearly
more data is needed for solid conclusions. In a study of 80
ethnic Chinese patients with NAFLD, serum resistin levels
were associated neither with presence of NASH nor with its
severity [85]. In a smaller study of 45 NAFLD patients and
50 controls, serum TNFa but not resistin was independently
associated with ﬁbrosis in NASH [86]. On the other hand,
resistinlevelswereassociatedwithﬁbrosisseverityinarecent
study from our group [73], while serum resistin levels were
higher in NAFLD than controls and positively correlated
withliverinﬂammationinanItalianstudy[87].Inthelargest
study so far, resistin was part of the biomarker panel for the
noninvasive diagnosis of NASH [78].
Regarding the remaining cytokines, data is yet scarce
and conﬁned to small patient numbers. IL-6 has gained
attention lately, after a small study of 35 patients (NASH:
18, NAFLD: 10, controls: 7), in which IL-6 liver expression
was markedly increased in NASH patients and positively
correlated with inﬂammation and ﬁbrosis [88]. In a study
of 36 morbidly obese patients and 12 healthy controls, IL-
6 was an independent predictor of steatosis and NASH
[89]. Finally, serum IL-6 was found signiﬁcantly elevated in
NAFLD than controls, even after correction for age, sex, and
BMI [90]. RBP4 serum levels were higher both in diabetic
and nondiabetic NAFLD patients compared to controls, but
no liver biopsy was performed and, therefore, histological
correlations were not available [91]. Finally, although serum
visfatin was lower in NASH than NAFLD patients and
healthy controls, it was not independently associated with
presence of NASH [86], while its levels positively correlated
withportalinﬂammation[92].Thepotentialroleofdiﬀerent
adipokines in NAFLD is summarized in Table 1.
4. Therapeutic Implications
Asithasbeenclearlyelucidated,adipokinesarekeyplayersin
the pathogenesis and progression of NAFLD. As there is no
eﬀective speciﬁc therapy for NASH, the use of drugs directly
targeting adipokines seems a reasonable option. To date, few
drugs have been tested towards that direction.
Pentoxifylline, a nonspeciﬁc TNFa inhibitor, was used
in a pilot study including 20 patients with NASH at a
daily dose of 1200mg [93]. A signiﬁcant decrease of serum
transaminases was noted after 12 months, but no follow-up
histology was available. A signiﬁcant proportion of patients
couldnottoleratethedrugduetonauseaandgastrointestinal
symptoms. Histological improvement was documented in
9 patients treated with a lower dose of pentoxifylline in
another recent study, in which adverse eﬀects were not
reported [94]. Inﬂiximab is a chimeric monoclonal antibody
that selectively and potently blocks TNFa. In experimental
models, it improves NASH lesions, and, therefore, its trial
in humans could be of interest [95]. The detrimental eﬀect
of inﬂiximab in patients of alcoholic hepatitis is a potential
concern [96].
Adiponectin exerts hepatoprotective actions in animal
models, and its administration could prove beneﬁcial in sub-
jects with NASH. Pioglitazone, which signiﬁcantly improvesMediators of Inﬂammation 5
NASH lesions, also increases adiponectin levels providing
indirect evidence of a potential adiponectin eﬀect [97].
Finally,ahumanizedIL-6receptorantibody,tocilizumab,
has been developed and successfully used in patients with
rheumatoid arthritis [98]. Its future trial in patients with
NASH would be helpful and welcome.
5. Conclusions
NAFLD represents a spectrum of disease from benign
fatty liver to NASH and even cirrhosis. The disease seems
to progress through a two- or even multiple-hit process,
with successive liver insults leading from fatty inﬁltra-
tion to inﬂammation and ﬁbrosis. The interplay of vari-
ous adipokines, the most important of which are leptin,
adiponectin, TNFa, resistin, and IL-6, has a key role in this
process. Clinical studies suggest that serum levels of the
above cytokines diﬀer among patients with NAFLD/NASH
and healthy controls. As liver biopsy remains the gold
standard for diagnosing NASH, the use of adipokines as
noninvasivediagnostictestisofinterest.Todate,adiponectin
has yielded the most promising results, but its use should
be validated in larger cohorts of patients. Finally, the use of
drugsthatspeciﬁcallytargetadipokinesremainsanattractive
possibility and a future challenge.
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